Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Drugs that suppress angiogenesis and hormonal activity may help faslodex overcome drug resistance
February 2nd, 2006
Drugs that suppress angiogenesis and hormonal activity may help faslodex overcome drug resistance. According to a study from the United States, "ICI 182,780 (faslodex), considered a pure anti-estrogen, is approved for treatment of post-menopausal breast cancer patients who fail to respond to tamoxifen therapy. We recently reported that, like mifepristone, ICI 182,780 exhibits anti-progestin activity, blocking the progestin-dependent increase in endogenous vascular endothelial growth factor (VEGF) mRNA and protein release." "Some anti-progestins have partial agonist-like activity in breast cancer cells expressing high levels of progesterone receptor B...
Source: Women's Health Weekly (2006-02-02)
|
